Business Information
The group's principal activities are to develop, manufacture and market automated genetic imaging systems for use in cytogenetic laboratories. These systems are used for cancer testing, prenatal testing and other genetic testing applications. The group's systems are sold to government and private clinical laboratories, research institutions, universities and pharmaceutical companies in the United States, Canada, Europe, Japan and other countries. The group also markets imaging systems, which are designed for use in plant and animal genetic research programs. In addition, the group introduced a clinical system to detect micrometastatic cancer cells in bone marrow from cancer patients. This system and its research capabilities assist physicians in determining the initial stages of cancer cases, in detecting disease recurrence and in genetically characterizing cancer cells. The customers include public and private clinical laboratories and research organizations.
|
|
Name |
Title
|
Email
|
| Robin Stracey | CEO, Pres. | N/A | | Terence Griffin | CFO | N/A |
|
|
Year |
Sales |
Net Income |
| 2005 | 20,093 | (1,027) | | 2004 | 20,640 | (3,303) | | 2003 | 18,959 | (2,796)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
